PF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market LaunchFDA Aligned with ENSC Manufacturing Path for PF614, Enabling Commercial Scale UpMPAR® Patent Protection Extended Through ...
New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer's Drug Development - POTOMAC, MARYLAND / ACCESS Newswire / January 5, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ...
In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS ...
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...
ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a ...
Orum Therapeutics (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief ...
Pharmaceutical Intermediates Market OverviewThe global pharmaceutical intermediates market is witnessing steady expansion as pharmaceutical manufacturing scales worldwide. Valued at approximately USD ...
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it received notice from the U.S. Food and Drug Administration's Center ...
A landmark, vendor-agnostic global benchmark delivering country-true insights on EHR and digital health performance across 147 countries, evaluating 70 vendors against 18 operational KPIs, independent ...
Creation of new Executive Vice President role integrating Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment HAMBURG, DE / ACCESS Newswire / ...
Baron & Budd President and Managing Shareholder Russell Budd, along with Shareholder and leader of the Environmental ...
The "Biological Therapies for Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global biological therapies market for cancer is expected to grow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback